ArticleBMC infectious diseases2026
Serum Interleukin-6 and Interleukin-10 levels in people living with HIV on short-term and long-term antiretroviral therapy: a comparative cross-sectional study with HIV-negative controls.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntiretroviral therapy (ART) suppresses HIV replication and partially restores immune function, but immune recovery is often incomplete. Interleukin-6 (IL-6) and Interleukin-10 (IL-10) reflect opposing sides of the immune response, pro-inflammatory and regulatory, respectively. They may provide insight into the degree of residual immune dysregulation in people living with HIV (PLHIV) on treatment. This study aims to determine serum IL-6 and IL-10 levels in PLHIV on ART compared to HIV-negative controls.
methodsA comparative cross-sectional study was conducted at the HIV Care and Treatment Clinic of the University of Port Harcourt Teaching Hospital (UPTH), Nigeria. Eighty-one participants were enrolled: 63 were living with HIV (27 on short-term ART [less than six months], 36 on long-term ART [two years or more]), and 18 HIV-negative controls. Serum IL-6 and IL-10 were quantified by enzyme-linked immunosorbent assay (ELISA). Group differences were assessed using one-way analysis of variance (ANOVA), Tukey HSD post hoc tests, and independent samples t-tests. The influence of age and sex on cytokine levels was examined by analysis of covariance (ANCOVA).
resultsIL-6 was 7.35 ± 0.17 pg/ml in the short-term ART group, 6.38 ± 0.12 pg/ml in the long-term ART group, and 5.65 ± 0.15 pg/ml in controls. All three pairwise comparisons were statistically significant (p < 0.05). IL-10 was 6.42 ± 0.15 pg/ml, 6.21 ± 0.11 pg/ml, and 5.81 ± 0.22 pg/ml across the same groups respectively. Only the comparison between the short-term ART group and controls was significant for IL-10. Age and sex had no statistically significant effect on either cytokine.
conclusionIL-6 declines with longer ART but remains elevated above control levels even after years of treatment, indicating persistent residual inflammation. Interleukin 10 is elevated in treated individuals compared with controls but does not track ART duration. These findings support the value of cytokine profiling as a supplementary tool for monitoring immune status in ART-treated PLHIV in a Nigerian clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.